Navigation Links
Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Date:1/16/2008

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB) announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase IIB grant from the National Science Foundation. The $500,000 grant will be used to continue to develop FAB's cell-free protein synthesis technology towards commercialization.

During Small Business Technology Transfer (STTR) Phase I and Phase II NSF projects, FAB successfully demonstrated that certain proteins could be made in a cell-free system in a soluble form, in a controllable and efficient fashion. With the Phase IIb grant, FAB will continue to develop the technology with a market-driven, therapeutic protein as FAB's first target product.

"We are pleased to receive this grant from the NSF," said Daniel S. Gold, PhD, CEO of FAB. "The grant will allow FAB to further develop and optimize our cell-free technology to enable the production of pharmaceutical protein therapeutics with the goal of improving their biological activity."

"This grant reflects NSF's continued interest in the commercialization potential of cell-free technology. The STTR Phase I and II grants were instrumental in supporting FAB's research initiatives to develop marketable biologics as a continuation of work initiated in my laboratory at the Department of Chemical Engineering at Stanford University," noted Professor James Swartz, D.Sc.

Intact organisms which have the limitation of having to maintain their own viability can have difficulty making toxic or difficult to fold proteins. Cell-free technology was designed to overcome these limitations.

About Fundamental Applied Biology

Fundamental Applied Biology (FAB), Inc. is creating opportunities for the development of novel protein-based therapeutics and vaccines using a proprietary cell-free protein synthesis technology. Cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics. FAB's goal is to become the leader in the field of cell-free protein synthesis by developing its own and collaborative therapies that will provide improved clinical outcomes for patients.

Contact:

Patricia Sinatra

VP, Business Development and Commercial Strategy

Fundamental Applied Biology, Inc.

(650) 329-9374

psinatra@cellfree.com

http://www.cellfree.com


'/>"/>
SOURCE Fundamental Applied Biology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
2. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
3. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
4. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
9. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
Breaking Medicine News(10 mins):